260 related articles for article (PubMed ID: 18221502)
1. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
Vié N; Copois V; Bascoul-Mollevi C; Denis V; Bec N; Robert B; Fraslon C; Conseiller E; Molina F; Larroque C; Martineau P; Del Rio M; Gongora C
Mol Cancer; 2008 Jan; 7():14. PubMed ID: 18221502
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Gervaz P; Rubbia-Brandt L; Andres A; Majno P; Roth A; Morel P; Mentha G
Ann Surg Oncol; 2010 Oct; 17(10):2714-9. PubMed ID: 20405223
[TBL] [Abstract][Full Text] [Related]
4. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
Volk J; Reinke F; van Kuilenburg AB; van Gennip AH; Schlichting C; Ganser A; Schöffski P
Ann Oncol; 2001 Apr; 12(4):569-71. PubMed ID: 11398894
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
[TBL] [Abstract][Full Text] [Related]
7. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
8. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
9. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
10. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
Volovat SR; Volovat C; Negru SM; Danciu M; Scripcariu V
J Chemother; 2016 Jun; 28(3):235-41. PubMed ID: 26018108
[TBL] [Abstract][Full Text] [Related]
12. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
13. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
Chazal M; Cheradame S; Formento JL; Francoual M; Formento P; Etienne MC; François E; Richelme H; Mousseau M; Letoublon C; Pezet D; Cure H; Seitz JF; Milano G
Clin Cancer Res; 1997 Apr; 3(4):553-7. PubMed ID: 9815719
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of PSAT1 as a potential prognostic factor for predicting clinical outcomes in patients with colorectal carcinoma.
Qian C; Xia Y; Ren Y; Yin Y; Deng A
Oncol Lett; 2017 Dec; 14(6):8014-8020. PubMed ID: 29344244
[TBL] [Abstract][Full Text] [Related]
15. [Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
Tsuchiya M; Watanabe M; Koike J; Kubota Y; Suzuki T; Otsuka Y; Tamura A; Maeda T; Shiokawa H; Arai K; Kurihara A; Funahashi K; Shimada H; Kaneko H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2594-7. PubMed ID: 21224650
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Berlin J; Posey J; Tchekmedyian S; Hu E; Chan D; Malik I; Yang L; Amado RG; Hecht JR
Clin Colorectal Cancer; 2007 Mar; 6(6):427-32. PubMed ID: 17531105
[TBL] [Abstract][Full Text] [Related]
17. Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
Okamoto H; Shiba S; Iino H; Sudoh M; Ichikawa D
Anticancer Res; 2021 Sep; 41(9):4505-4513. PubMed ID: 34475076
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
Pozzo C; Basso M; Cassano A; Quirino M; Schinzari G; Trigila N; Vellone M; Giuliante F; Nuzzo G; Barone C
Ann Oncol; 2004 Jun; 15(6):933-9. PubMed ID: 15151951
[TBL] [Abstract][Full Text] [Related]
20. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
